hexane-1,2,4-triol | 44815-64-7

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: hexane-1,2,4-triol
• 英文别名: α.β.δ-Trioxy-hexan；Hexan-1,2,4-triol；1,2,4-Hexanetriol
• CAS: 44815-64-7
• 化学式: C₆H₁₄O₃
• 分子量: 134.175
• InChiKey: DZZRNEZNZCRBOT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.4
• 重原子数：
  9
• 可旋转键数：
  4
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  60.7
• 氢给体数：
  3
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  5-己烯-3-醇 在 potassium permanganate 作用下， 生成 hexane-1,2,4-triol
  参考文献：
  名称：

  Fournier, Bulletin de la Societe Chimique de France, 1895, vol. <3> 13, p. 121

  摘要：

  DOI：

文献信息

• [EN] CYCLIC CARBONYL COMPOUNDS WITH PENDANT PENTAFLUOROPHENYL CARBONATE GROUPS, PREPARATIONS THEREOF, AND POLYMERS THEREFROM<br/>[FR] COMPOSÉS CARBONYLÉS CYCLIQUES AVEC GROUPEMENTS PENTAFLUOROPHÉNYLCARBONATE PENDANTS, LEURS SYNTHÈSES ET LEURS POLYMÈRES
  申请人：IBM

  公开号：WO2011135046A1

  公开（公告）日：2011-11-03

  A one pot method of preparing cyclic carbonyl compounds comprising an active pendant pentafluorophenyl carbonate group is disclosed. The cyclic carbonyl compounds can be polymerized by ring opening methods to form ROP polymers comprising repeat units comprising a side chain pentafluorophenyl carbonate group. Using a suitable nucleophile, the pendant pentafluorophenyl carbonate group can be selectively transformed into a variety of other functional groups before or after the ring opening polymerization.

  揭示了一种制备含有活性吊挂五氟苯基碳酸酯基团的环状羰基化合物的一锅法。这些环状羰基化合物可以通过环开启方法聚合，形成包含侧链五氟苯基碳酸酯基团的ROP聚合物重复单元。利用适当的亲核试剂，吊挂的五氟苯基碳酸酯基团可以在环开启聚合之前或之后被选择性地转化为各种其他功能基团。
• ACTIVE-ENERGY-RAY-POLYMERIZABLE INITIATOR, ACTIVE-ENERGY-RAY-POLYMERIZABLE COMPOSITION, ACTIVE-ENERGY-RAY-POLYMERIZABLE INK, INK STORAGE CONTAINER, IMAGE FORMING METHOD, AND IMAGE FORMING APPARATUS
  申请人：HARADA Shigeyuki

  公开号：US20200270469A1

  公开（公告）日：2020-08-27

  An active-energy-ray-polymerizable initiator having a structure represented by the following general formula (1) is provided. In general formula (1), L 1 represents —C(═O)—O— (binding to L 2 side) or —O—, L 2 represents —O(CH 2 ) p -(binding to L 1 side), —(OC 2 H 4 ) n -(binding to L 1 side), or —(OC 3 H 6 ) m -(binding to L 1 side), where p represents an integer of 2 to 16, n represents an integer of 2 to 12, and m represents 2 or 3, L 3 represents a direct binding or —NH—, L 4 represents —OC 2 H 4 -(binding to L 3 side) or —(OC 2 H 4 ) 2 -(binding to L 3 side), and R represents —H or —CH 3 .

  提供具有以下一般式（1）所代表的结构的活性能量射线可聚合引发剂。 在一般式（1）中，L1代表—C(═O)—O—（与L2侧结合）或—O—，L2代表—O(CH2)p-(与L1侧结合)，—(OC2H4)n-(与L1侧结合)，或—(OC3H6)m-(与L1侧结合)，其中p表示2到16的整数，n表示2到12的整数，m表示2或3，L3代表直接结合或—NH—，L4代表—OC2H4-(与L3侧结合)或—(OC2H4)2-(与L3侧结合)，R代表—H或—CH3。
• ORGANIC COLORANT, COLORING COMPOSITION, AND INKJET INK
  申请人：Fujita Takuya

  公开号：US20190010331A1

  公开（公告）日：2019-01-10

  Organic colorant represented by General Formula (1) below: where in the General Formula (1), R 1 and R 2 each independently represent C1-C20 alkyl group, C1-C20 alkenyl group, phenyl group, naphthyl group, or group represented by —(CH 2 ) n —COO—R 3 , —(CH 2 ) n —R 4 , —(CH 2 ) n —CONH—R 5 , —CR 6 R 7 —COO—R 8 , or —(CH 2 ) n —OCOCH 3 ; R 3 represents hydrogen atom or C1-C2 alkyl group; R 4 represents hydroxy group, C1-C2 alkoxy group, C2-C5 alkenyloxy group, SO 3 Na group, OSO 3 Na group, phenyl group, phenylalkyl group, naphthyl group, or naphthylalkyl group; R 5 represents C1-C20 alkyl group, C1-C20 alkenyl group, or C1-C12 hydroxyalkyl group; R 6 represents hydrogen atom or methyl group; R 7 represents C1-C4 alkyl group; R 8 represents C1-C5 alkyl group; and n is integer of from 1 to 12.

  以下是通式（1）所代表的有机染料： 在通式（1）中，R1和R2各自独立地代表C1-C20烷基，C1-C20烯基，苯基，萘基，或由—（CH2）n—COO—R3，—（CH2）n—R4，—（CH2）n—CONH—R5，—CR6R7—COO—R8或—（CH2）n—OCOCH3所代表的基团；R3代表氢原子或C1-C2烷基；R4代表羟基，C1-C2烷氧基，C2-C5烯氧基，SO3Na基团，OSO3Na基团，苯基，苯基烷基，萘基或萘基烷基；R5代表C1-C20烷基，C1-C20烯基或C1-C12羟基烷基；R6代表氢原子或甲基基团；R7代表C1-C4烷基；R8代表C1-C5烷基；n为1至12的整数。
• Complexes made using low solubility drugs
  申请人：Wong S.L. Patrick

  公开号：US20060134204A1

  公开（公告）日：2006-06-22

  Disclosed herein are substances that include a complex that includes a drug moiety ionically bound to a counter-ion; wherein a solubility of the complex is greater than a solubility of the drug moiety. Also disclosed are compositions and dosage forms made from such substances and complexes; methods of making compositions, substances, and complexes; and methods of administering the same to patients.

  本文揭示了一种物质，其中包括一种复合物，该复合物包括离子键合的药物基团和对离子；其中复合物的溶解度大于药物基团的溶解度。还揭示了由这种物质和复合物制成的组合物和剂型；制备组合物、物质和复合物的方法；以及将其用于患者的方法。
• Methods and dosage forms for controlled delivery of paliperidone and risperidone
  申请人：Yam V. Nyomi

  公开号：US20050232995A1

  公开（公告）日：2005-10-20

  Dosage forms and methods for providing a substantially ascending rate of release of paliperidone or risperidone are provided. The sustained release dosage forms provide therapeutically effective average steady-state plasma paliperidone or risperidone concentrations when administered once per day. This once-a-day dosing regimen results in only one peak plasma paliperidone or risperidone concentration occurrence in each 24 hour period. In addition, the peak plasma paliperidone or risperidone concentration occurs at a later time following dose administration and exhibits a lesser magnitude than the peak plasma paliperidone or risperidone concentration that occurs following administration of paliperidone or risperidone in an immediate-release dosage form.

  本发明提供了用于提供相对升高的帕利哌酮或利培酮释放速率的剂型和方法。这种持续释放的剂型在每天一次的给药时提供治疗有效的平均稳态血浆帕利哌酮或利培酮浓度。这种一天一次的给药方案只会在每24小时内发生一次峰值血浆帕利哌酮或利培酮浓度。此外，峰值血浆帕利哌酮或利培酮浓度发生在给药后的较晚时间，并且比即时释放剂型的峰值血浆帕利哌酮或利培酮浓度具有较小的幅度。